L&C BIO Co.,LTD (KOSDAQ:290650)
South Korea · Delayed Price · Currency is KRW 76,200
-700 (-0.91%)
Jun 15, 2026, 3:30 PM KST
L&C BIO Co.,LTD Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 98,100 | 85,476 | 72,032 | 65,927 | 52,572 | 45,677 |
Other Revenue | 0 | - | - | - | -0 | - |
| 98,100 | 85,476 | 72,032 | 65,927 | 52,572 | 45,677 | |
Revenue Growth (YoY) | 34.07% | 18.66% | 9.26% | 25.40% | 15.10% | 38.53% |
Cost of Revenue | 44,112 | 40,088 | 36,357 | 32,070 | 25,581 | 17,227 |
Gross Profit | 53,989 | 45,389 | 35,676 | 33,856 | 26,992 | 28,450 |
Selling, General & Admin | 35,139 | 32,781 | 24,604 | 20,476 | 13,941 | 12,057 |
Research & Development | 4,109 | 4,102 | 4,907 | 3,152 | 2,195 | 2,295 |
Amortization of Goodwill & Intangibles | 720.31 | 640.81 | 469.23 | 395.16 | 358.64 | 238.28 |
Operating Expenses | 44,384 | 41,973 | 31,807 | 25,727 | 17,508 | 15,280 |
Operating Income | 9,604 | 3,416 | 3,869 | 8,129 | 9,484 | 13,170 |
Interest Expense | -5,866 | -5,866 | -3,221 | -6,173 | -3,076 | -460.27 |
Interest & Investment Income | 1,643 | 1,643 | 1,617 | 1,551 | 666.06 | 431.77 |
Earnings From Equity Investments | -250 | -250 | - | - | - | - |
Currency Exchange Gain (Loss) | 139.73 | 139.73 | -834.65 | 185.28 | -271.63 | -58.41 |
Other Non Operating Income (Expenses) | -87,482 | -85,135 | 186.69 | 85.1 | 231.71 | 302.06 |
EBT Excluding Unusual Items | -82,211 | -86,052 | 1,617 | 3,778 | 7,034 | 13,385 |
Gain (Loss) on Sale of Investments | -1,231 | -1,026 | 138,415 | 61,740 | -2,546 | 3,667 |
Gain (Loss) on Sale of Assets | -435.99 | -435.99 | -210.53 | 170.77 | 75.75 | 42.98 |
Asset Writedown | -72,520 | -72,520 | - | -2,423 | - | - |
Pretax Income | -156,398 | -160,034 | 139,822 | 63,266 | 4,563 | 17,095 |
Income Tax Expense | -21,161 | -21,677 | -5,117 | 14,407 | -1,129 | 1,515 |
Earnings From Continuing Operations | -135,237 | -138,357 | 144,939 | 48,859 | 5,692 | 15,580 |
Earnings From Discontinued Operations | 358.21 | 110.03 | -3,442 | -328 | - | - |
Net Income to Company | -134,879 | -138,247 | 141,497 | 48,531 | 5,692 | 15,580 |
Minority Interest in Earnings | -265.56 | 71.99 | 99.14 | -170.47 | -1,148 | -1,766 |
Net Income | -135,144 | -138,175 | 141,596 | 48,361 | 4,544 | 13,814 |
Net Income to Common | -135,144 | -138,175 | 141,596 | 48,361 | 4,544 | 13,814 |
Net Income Growth | - | - | 192.79% | 964.24% | -67.11% | 27.76% |
Shares Outstanding (Basic) | 24 | 24 | 23 | 23 | 23 | 22 |
Shares Outstanding (Diluted) | 24 | 24 | 23 | 25 | 23 | 22 |
Shares Change (YoY) | 4.78% | 4.81% | -8.24% | 8.98% | 1.74% | 1.83% |
EPS (Basic) | -5619.61 | -5811.40 | 6241.85 | 2131.86 | 200.32 | 619.55 |
EPS (Diluted) | -5627.49 | -5819.37 | 6195.26 | 2093.45 | 200.00 | 619.55 |
EPS Growth | - | - | 195.94% | 946.73% | -67.72% | 25.46% |
Free Cash Flow | -3,052 | -3,245 | -13,282 | -36,636 | -43,607 | 655.69 |
Free Cash Flow Per Share | -126.92 | -136.49 | -585.50 | -1481.90 | -1922.29 | 29.41 |
Dividend Per Share | 50.000 | 50.000 | - | - | - | - |
Gross Margin | 55.03% | 53.10% | 49.53% | 51.35% | 51.34% | 62.29% |
Operating Margin | 9.79% | 4.00% | 5.37% | 12.33% | 18.04% | 28.83% |
Profit Margin | -137.76% | -161.65% | 196.57% | 73.36% | 8.64% | 30.24% |
Free Cash Flow Margin | -3.11% | -3.80% | -18.44% | -55.57% | -82.95% | 1.44% |
EBITDA | 18,021 | 11,650 | 10,623 | 13,784 | 13,992 | 16,072 |
EBITDA Margin | 18.37% | 13.63% | 14.75% | 20.91% | 26.61% | 35.19% |
D&A For EBITDA | 8,416 | 8,234 | 6,754 | 5,654 | 4,508 | 2,902 |
EBIT | 9,604 | 3,416 | 3,869 | 8,129 | 9,484 | 13,170 |
EBIT Margin | 9.79% | 4.00% | 5.37% | 12.33% | 18.04% | 28.83% |
Effective Tax Rate | - | - | - | 22.77% | - | 8.86% |
Advertising Expenses | - | 2,274 | 1,554 | 1,336 | 723.78 | 363.15 |